The table below shows Kymera Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$39.21M
$47.07M
$78.59M
$46.83M
$72.83M
$34.03M
Cost of revenue
$39.21M
$47.07M
$78.59M
$46.83M
-
-
Gross profit
-
-
-
-
-
-
R&D
$316.57M
$240.25M
$189.08M
$164.25M
$137.02M
$62.10M
SG&A
KYMR annual revenue (10-K history)
Kymera Therapeutics, Inc. reported annual revenue of $39.21M for fiscal year 2025. That is down 16.7% from $47.07M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $2.93M (FY 2019) to $39.21M. Figures come from the company's audited annual reports as filed with the SEC.
